OSAKA, Japan — Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) announced that efficacy signals for ONO-2808, a S1P5 receptor agonist, were observed in the interim analysis of the Phase 2 clinical trial (ONO-2808-03 study) which assessed the safety and efficacy of ONO-2808 compared to...
Latest News
PRINCETON, N.J. & ALAMEDA, Calif. — Bristol Myers Squibb and Exelixis, Inc. today announced four-year follow-up results from the CheckMate -9ER trial evaluating Opdivo® (nivolumab) in combination with CABOMETYX® (cabozantinib) vs. sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC). Results continued to show superior progression-free...
By Louise Rodino-Klapac – PhD President of Research & Development at Sarepta Therapeutics Cambridge, Mass. – Momentum in Duchenne muscular dystrophy was palpable at the Muscular Dystrophy Association Scientific Congress last month. With nearly 180 abstracts focused on Duchenne alone, spanning pre-clinical research to post-market experience, the field is at...
Philadelphia, PA – Millions of people living with neurodegenerative diseases and their loved ones have long hoped for the day when treatments could change the prognosis from an inevitable decline to a managed, stable condition. The urgent need for life-changing therapies exists against the backdrop of a growing prevalence of...
SOUTH SAN FRANCISCO, Calif. — Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics, today announced that OPN-2853, a bromodomain and extra-terminal motif (BET) small molecule inhibitor, has been granted Orphan Drug Designation (ODD) for the treatment of myelofibrosis (MF) by the U.S....
SAN DIEGO, Calif. — Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer therapeutics, presented promising preclinical data in two programs, OPN-6602, a dual EP300/CBP inhibitor in multiple myeloma, and OPN-9840, an oral, non-covalent TEAD inhibitor in malignant mesothelioma and metastatic melanoma. Data were...
SINGAPORE – Keeping blood pressure in check could save lives among Asian adults with type 2 diabetes, suggests a sizable new study of more than 80,000 patients in Singapore. But how low should it go? A new study led by Duke-NUS Medical School—published in the Journal of the American Heart...
BEIJING & CAMBRIDGE, Mass. – CANbridge Pharmaceuticals, Inc., a biopharmaceutical company developing and commercializing innovative drugs to treat rare diseases and rare cancers in China and globally, announced that it has entered into a strategic collaboration and licensing agreement with LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company...
RESEARCH TRIANGLE PARK, N.C. — Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, today announced a strategic partnership with the Global RDH12 Alliance (the Alliance) to advance Opus’ gene therapy program...
RESEARCH TRIANGLE PARK, N.C. — Opus Genetics, (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that the first participant has been dosed in the Company’s OPGx-BEST1 Phase 1/2 clinical...